Streetbeat News

Stock Prices

ACB

GNLN

PMD

SMG

XXII

The article reports on the performance of various cannabis stocks on July 31, 2024. Notable gainers include Elixinol Wellness, AusCann Group Holdings, and Scotts Miracle Gro, while significant losers include Empower Clinics, Pharmadrug, and Psychemedics.

Portfolio Pulse from Benzinga Insights

July 31, 2024 | 8:30 pm

IVT

InvenTrust Properties (NYSE: IVT) reported Q2 2024 earnings per share of $0.43, surpassing the analyst estimate of $0.41. The company also reported sales of $67.423 million, exceeding the estimate of $66.716 million and marking a 4.23% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:30 pm

ALGT

Allegiant Travel Company has revised its Q3 earnings per share (EPS) forecast to a range of $(3.50) to $(2.50), significantly below the estimated $0.64.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:29 pm

COHU

Cohu Inc. has announced its expected Q3 sales to be $95 million, with a margin of error of plus or minus $5 million. This is below the estimated $107.2 million.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:29 pm

VNDA

Vanda Pharmaceuticals (NASDAQ:VNDA) reported Q2 2024 GAAP EPS of $(0.08), beating the estimate of $(0.21) by 61.9%. Sales were $50.474M, surpassing the $47.860M estimate and showing a 9.59% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:28 pm

CCRN

Cross Country Healthcare has provided guidance for Q3 2024 adjusted EPS in the range of $0.08 to $0.12, which is below the analyst estimate of $0.13.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:27 pm

ACLS

Axcelis Technologies (NASDAQ:ACLS) reported Q2 2024 GAAP EPS of $1.55, beating the estimate of $1.35. Sales were $256.512M, surpassing the $250.302M estimate. Despite the beats, sales decreased by 6.37% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:26 pm

EVTC

Evertec has provided its financial guidance for FY24, projecting revenue between $846M and $854M, which is in line with the market estimate of $850.49M. The company also expects adjusted EPS to be in the range of $2.98 to $3.07, surpassing the market estimate of $2.90.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:26 pm

CCRN

Cross Country Healthcare (NASDAQ:CCRN) reported Q2 2024 earnings per share of $0.10, missing the analyst estimate of $0.13 by 23.08%. However, the company reported sales of $339.77 million, beating the estimate of $334.76 million by 1.50%. This represents a 37.16% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:26 pm

GKOS

Glaukos Corporation has provided its revenue guidance for FY24, expecting net sales to be in the range of $370 million to $376 million, surpassing the estimated $363.02 million.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:26 pm